SCHEMBL1607367

SCHEMBL1607367

CS(=O)(=O)c1ccc(Cn2cc(C(=O)Nc3nccs3)c3ccccc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
NPC1 O15118 5/20 0.56
RAB9A P51151 5/20 0.56
NPSR1 Q6W5P4 4/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
AHR P35869 1/20 0.52
LMNA P02545 2/20 0.50
POLB P06746 2/20 0.50
USP2 O75604 1/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.50
MAPT P10636 2/20 0.49
GCK P35557 2/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
SCN3A Q9NY46 2/20 0.45
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1606612 0.88 NPSR1 (0.68) ALDH1A1NPC1RAB9ANPSR1MEN1
SCHEMBL1606981 0.87 MEN1 (0.49) ALDH1A1NPC1RAB9ANPSR1MEN1
SCHEMBL2659741 0.87 NPSR1 (0.59) ALDH1A1NPC1RAB9ANPSR1MEN1
SCHEMBL1605893 0.86 ALDH1A1 (0.58) ALDH1A1NPC1RAB9ANPSR1MEN1
SCHEMBL1606880 0.86 ALDH1A1 (0.57) ALDH1A1NPC1RAB9ANPSR1MEN1
SCHEMBL1607277 0.82 NPC1 (0.51) ALDH1A1NPC1RAB9ANPSR1MEN1
SCHEMBL1607346 0.82 ALDH1A1 (0.58) ALDH1A1NPC1RAB9ANPSR1MEN1
SCHEMBL26494946 0.82 ALOX15 (0.56) ALDH1A1NPC1RAB9ANPSR1MEN1
SCHEMBL3432034 0.81 KMT2A (0.51) ALDH1A1NPC1RAB9ANPSR1MEN1
SCHEMBL1607776 0.80 NPSR1 (0.56) ALDH1A1NPC1RAB9ANPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148413-B2 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes TRANSTECH PHARMA, INC. (US) 2012-04-03 US disclosed
US-8148413-B2 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes TRANSTECH PHARMA, INC. (US) 2012-04-03 US disclosed
US-20110082144-A1 N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES TRANSTECH PHARMA, INC. (US) 2011-04-07 US disclosed
US-20110082144-A1 N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES TRANSTECH PHARMA, INC. (US) 2011-04-07 US disclosed
US-7812043-B2 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes TRANSTECH PHARMA, INC. (US) 2010-10-12 US disclosed
US-7812043-B2 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes TRANSTECH PHARMA, INC. (US) 2010-10-12 US disclosed
US-7812043-B2 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes TRANSTECH PHARMA, INC. (US) 2010-10-12 US disclosed
US-20070027140-A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes NOVO NORDISK A/S (DK) 2007-02-01 US disclosed
US-20070027140-A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes NOVO NORDISK A/S (DK) 2007-02-01 US disclosed
US-20070027140-A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes NOVO NORDISK A/S (DK) 2007-02-01 US disclosed
EP-1689392-A1 N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES NOVO NORDISK A/S (DK) 2006-08-16 EP disclosed
WO-2005049019-A1 N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES NOVO NORDISK A/S (DK) 2005-06-02 WO disclosed
WO-2005049019-A1 N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES NOVO NORDISK A/S (DK) 2005-06-02 WO disclosed
EP-1532980-A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes NOVO NORDISK A/S (DK) 2005-05-25 EP disclosed
EP-1532980-A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes NOVO NORDISK A/S (DK) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027140-A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes GALK1, GCKR, GCK ALDH1A1 2638/4885NPC1 4060/4885RAB9A 4493/4885
US-20110082144-A1 N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES GCKR, GCK, GALK1 ALDH1A1 1240/4885NPC1 3131/4885RAB9A 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.